enlightenVue

Executive Summary

enlightenVue is a privately held medical device company headquartered in Cambridge, Massachusetts, developing the SurgiVue platform for ophthalmic surgery. The platform integrates both diagnostic and therapeutic capabilities into a single procedure, leveraging the industry's smallest working diameter (2 mm) endoscope with two working channels and flush ports, as well as superior optics. This design enables minimally invasive access to the eye's interior, potentially reducing trauma, improving visualization, and streamlining surgical workflows. The technology addresses a significant unmet need in ophthalmology, where simultaneous visualization and intervention can enhance outcomes for conditions such as glaucoma, cataract, and retinal disorders. With a founding in 2018, enlightenVue is in an early stage but holds promise to disrupt current surgical paradigms by offering a versatile tool that could substitute multiple devices and reduce procedure times. The company's focus on innovation and compact design positions it well within the competitive ophthalmic device landscape, though it likely faces challenges related to regulatory clearance, clinical adoption, and commercial scaling. Overall, enlightenVue represents a compelling investment opportunity for those seeking exposure to next-generation ophthalmic surgical technologies.

Upcoming Catalysts (preview)

• Q2 2026FDA 510(k) Clearance or Breakthrough Device Designation70% success
• Q3 2026Initial Clinical Study Results Publication60% success
• H2 2026Strategic Partnership with Major Ophthalmic Device Company40% success